리포솜 독소루비신 : 세계 시장 점유율과 순위, 총판매량 및 수요 예측(2025-2031년)

The global market for Liposomal Doxorubicin was estimated to be worth US$ 974 million in 2024 and is forecast to a readjusted size of US$ 724 million by 2031 with a CAGR of -3.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Liposomal Doxorubicin cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Liposomal doxorubicin is a chemotherapeutic drug in which doxorubicin, a widely used anthracycline antibiotic for cancer treatment, is encapsulated within liposomes-tiny, spherical lipid-based vesicles. This liposomal formulation enhances the drug's delivery to tumor tissues, prolongs circulation time in the bloodstream, and reduces cardiotoxicity and other systemic side effects commonly associated with conventional doxorubicin. It is used to treat various cancers, including ovarian cancer, breast cancer, multiple myeloma, and Kaposi's sarcoma, particularly in patients who are sensitive to the adverse effects of standard chemotherapy.

A key driver of the liposomal doxorubicin market is the increasing demand for safer and more effective cancer therapies that minimize systemic toxicity while maintaining therapeutic efficacy. Traditional doxorubicin, though widely used in oncology, is associated with severe adverse effects, particularly dose-limiting cardiotoxicity. The liposomal formulation addresses this issue by encapsulating doxorubicin in lipid bilayers, enabling targeted delivery to tumor sites while reducing exposure to healthy tissues. This significantly enhances the drug's safety profile and patient tolerability, especially in long-term or combination chemotherapy regimens. The growing global burden of cancer-driven by aging populations, lifestyle changes, and better diagnostic capabilities-has led to a surge in demand for advanced oncologic treatments, further propelling the use of liposomal formulations. Additionally, the increasing adoption of personalized medicine and targeted drug delivery systems aligns well with liposomal drug technologies, positioning liposomal doxorubicin as a preferred choice in indications such as metastatic breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma. Regulatory approvals and clinical evidence supporting its efficacy in both first-line and salvage therapy settings are also contributing to broader market acceptance and use.

Despite its therapeutic advantages, the liposomal doxorubicin market faces several notable challenges. One of the primary hurdles is the high cost of liposomal drug development and production, which involves complex manufacturing processes and strict quality controls to ensure stability, bioavailability, and batch consistency. This results in a significantly higher price point compared to conventional chemotherapy, which can limit accessibility-particularly in low- and middle-income countries or healthcare systems with constrained budgets. Moreover, the availability of generic liposomal doxorubicin products in some markets has led to pricing pressure and increased competition, raising concerns over market share and profit margins for originator brands like Doxil (Caelyx in Europe). Supply chain issues and past shortages of liposomal doxorubicin have also disrupted treatment continuity for patients and eroded confidence in product availability. Additionally, regulatory complexities related to bioequivalence and product substitution of liposomal formulations pose challenges for market entry and approval of generics. From a clinical perspective, while liposomal doxorubicin reduces cardiotoxicity, it may introduce other adverse effects such as palmar-plantar erythrodysesthesia (hand-foot syndrome), which can impact patient compliance. Addressing these challenges will require continued investment in formulation innovation, cost-effective manufacturing, regulatory harmonization, and real-world outcome data to support the broader adoption of liposomal chemotherapeutics.

This report aims to provide a comprehensive presentation of the global market for Liposomal Doxorubicin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Liposomal Doxorubicin by region & country, by Type, and by Application.

The Liposomal Doxorubicin market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal Doxorubicin.

Market Segmentation

By Company

• Johnson & Johnson
• Sun Pharmaceutical
• CSPC
• Kinyond
• Teva
• Fudan-Zhangjiang
• Zydus Cadila
• TTY Biopharma
• Baxter International
• Nippon Kayaku

Segment by Type

• 5 ml
• 10 ml
• 25 ml

Segment by Application

• Breast Cancer
• Liver Cancer
• Kidney Cancer
• Multiple Myeloma
• Ovarian Cancer
• Other

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Liposomal Doxorubicin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Liposomal Doxorubicin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Liposomal Doxorubicin in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Liposomal Doxorubicin Product Introduction
• 1.2 Global Liposomal Doxorubicin Market Size Forecast
  • 1.2.1 Global Liposomal Doxorubicin Sales Value (2020-2031)
  • 1.2.2 Global Liposomal Doxorubicin Sales Volume (2020-2031)
  • 1.2.3 Global Liposomal Doxorubicin Sales Price (2020-2031)
• 1.3 Liposomal Doxorubicin Market Trends & Drivers
  • 1.3.1 Liposomal Doxorubicin Industry Trends
  • 1.3.2 Liposomal Doxorubicin Market Drivers & Opportunity
  • 1.3.3 Liposomal Doxorubicin Market Challenges
  • 1.3.4 Liposomal Doxorubicin Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Liposomal Doxorubicin Players Revenue Ranking (2024)
• 2.2 Global Liposomal Doxorubicin Revenue by Company (2020-2025)
• 2.3 Global Liposomal Doxorubicin Players Sales Volume Ranking (2024)
• 2.4 Global Liposomal Doxorubicin Sales Volume by Company Players (2020-2025)
• 2.5 Global Liposomal Doxorubicin Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Liposomal Doxorubicin Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Liposomal Doxorubicin Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Liposomal Doxorubicin
• 2.9 Liposomal Doxorubicin Market Competitive Analysis
  • 2.9.1 Liposomal Doxorubicin Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Liposomal Doxorubicin Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal Doxorubicin as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 5 ml
  • 3.1.2 10 ml
  • 3.1.3 25 ml
• 3.2 Global Liposomal Doxorubicin Sales Value by Type
  • 3.2.1 Global Liposomal Doxorubicin Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Liposomal Doxorubicin Sales Value, by Type (2020-2031)
  • 3.2.3 Global Liposomal Doxorubicin Sales Value, by Type (%) (2020-2031)
• 3.3 Global Liposomal Doxorubicin Sales Volume by Type
  • 3.3.1 Global Liposomal Doxorubicin Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Liposomal Doxorubicin Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Liposomal Doxorubicin Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Liposomal Doxorubicin Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Breast Cancer
  • 4.1.2 Liver Cancer
  • 4.1.3 Kidney Cancer
  • 4.1.4 Multiple Myeloma
  • 4.1.5 Ovarian Cancer
  • 4.1.6 Other
• 4.2 Global Liposomal Doxorubicin Sales Value by Application
  • 4.2.1 Global Liposomal Doxorubicin Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Liposomal Doxorubicin Sales Value, by Application (2020-2031)
  • 4.2.3 Global Liposomal Doxorubicin Sales Value, by Application (%) (2020-2031)
• 4.3 Global Liposomal Doxorubicin Sales Volume by Application
  • 4.3.1 Global Liposomal Doxorubicin Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Liposomal Doxorubicin Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Liposomal Doxorubicin Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Liposomal Doxorubicin Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Liposomal Doxorubicin Sales Value by Region
  • 5.1.1 Global Liposomal Doxorubicin Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Liposomal Doxorubicin Sales Value by Region (2020-2025)
  • 5.1.3 Global Liposomal Doxorubicin Sales Value by Region (2026-2031)
  • 5.1.4 Global Liposomal Doxorubicin Sales Value by Region (%), (2020-2031)
• 5.2 Global Liposomal Doxorubicin Sales Volume by Region
  • 5.2.1 Global Liposomal Doxorubicin Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Liposomal Doxorubicin Sales Volume by Region (2020-2025)
  • 5.2.3 Global Liposomal Doxorubicin Sales Volume by Region (2026-2031)
  • 5.2.4 Global Liposomal Doxorubicin Sales Volume by Region (%), (2020-2031)
• 5.3 Global Liposomal Doxorubicin Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Liposomal Doxorubicin Sales Value, 2020-2031
  • 5.4.2 North America Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Liposomal Doxorubicin Sales Value, 2020-2031
  • 5.5.2 Europe Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Liposomal Doxorubicin Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Liposomal Doxorubicin Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Liposomal Doxorubicin Sales Value, 2020-2031
  • 5.7.2 South America Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Liposomal Doxorubicin Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Liposomal Doxorubicin Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Liposomal Doxorubicin Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Liposomal Doxorubicin Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Liposomal Doxorubicin Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Liposomal Doxorubicin Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Liposomal Doxorubicin Sales Value, 2020-2031
  • 6.3.2 United States Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Liposomal Doxorubicin Sales Value, 2020-2031
  • 6.4.2 Europe Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Liposomal Doxorubicin Sales Value, 2020-2031
  • 6.5.2 China Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Liposomal Doxorubicin Sales Value, 2020-2031
  • 6.6.2 Japan Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Liposomal Doxorubicin Sales Value, 2020-2031
  • 6.7.2 South Korea Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Liposomal Doxorubicin Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Liposomal Doxorubicin Sales Value, 2020-2031
  • 6.9.2 India Liposomal Doxorubicin Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Liposomal Doxorubicin Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Johnson & Johnson
  • 7.1.1 Johnson & Johnson Company Information
  • 7.1.2 Johnson & Johnson Introduction and Business Overview
  • 7.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Johnson & Johnson Liposomal Doxorubicin Product Offerings
  • 7.1.5 Johnson & Johnson Recent Development
• 7.2 Sun Pharmaceutical
  • 7.2.1 Sun Pharmaceutical Company Information
  • 7.2.2 Sun Pharmaceutical Introduction and Business Overview
  • 7.2.3 Sun Pharmaceutical Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Sun Pharmaceutical Liposomal Doxorubicin Product Offerings
  • 7.2.5 Sun Pharmaceutical Recent Development
• 7.3 CSPC
  • 7.3.1 CSPC Company Information
  • 7.3.2 CSPC Introduction and Business Overview
  • 7.3.3 CSPC Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 CSPC Liposomal Doxorubicin Product Offerings
  • 7.3.5 CSPC Recent Development
• 7.4 Kinyond
  • 7.4.1 Kinyond Company Information
  • 7.4.2 Kinyond Introduction and Business Overview
  • 7.4.3 Kinyond Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Kinyond Liposomal Doxorubicin Product Offerings
  • 7.4.5 Kinyond Recent Development
• 7.5 Teva
  • 7.5.1 Teva Company Information
  • 7.5.2 Teva Introduction and Business Overview
  • 7.5.3 Teva Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Teva Liposomal Doxorubicin Product Offerings
  • 7.5.5 Teva Recent Development
• 7.6 Fudan-Zhangjiang
  • 7.6.1 Fudan-Zhangjiang Company Information
  • 7.6.2 Fudan-Zhangjiang Introduction and Business Overview
  • 7.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Fudan-Zhangjiang Liposomal Doxorubicin Product Offerings
  • 7.6.5 Fudan-Zhangjiang Recent Development
• 7.7 Zydus Cadila
  • 7.7.1 Zydus Cadila Company Information
  • 7.7.2 Zydus Cadila Introduction and Business Overview
  • 7.7.3 Zydus Cadila Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Zydus Cadila Liposomal Doxorubicin Product Offerings
  • 7.7.5 Zydus Cadila Recent Development
• 7.8 TTY Biopharma
  • 7.8.1 TTY Biopharma Company Information
  • 7.8.2 TTY Biopharma Introduction and Business Overview
  • 7.8.3 TTY Biopharma Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 TTY Biopharma Liposomal Doxorubicin Product Offerings
  • 7.8.5 TTY Biopharma Recent Development
• 7.9 Baxter International
  • 7.9.1 Baxter International Company Information
  • 7.9.2 Baxter International Introduction and Business Overview
  • 7.9.3 Baxter International Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Baxter International Liposomal Doxorubicin Product Offerings
  • 7.9.5 Baxter International Recent Development
• 7.10 Nippon Kayaku
  • 7.10.1 Nippon Kayaku Company Information
  • 7.10.2 Nippon Kayaku Introduction and Business Overview
  • 7.10.3 Nippon Kayaku Liposomal Doxorubicin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Nippon Kayaku Liposomal Doxorubicin Product Offerings
  • 7.10.5 Nippon Kayaku Recent Development

8 Industry Chain Analysis

• 8.1 Liposomal Doxorubicin Industrial Chain
• 8.2 Liposomal Doxorubicin Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Liposomal Doxorubicin Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Liposomal Doxorubicin Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer